What are the options if you want to be able to use the UPC?

No items found.

November 3, 2022

Download PDF

Table of contents

Toc Heading
Toc Heading

No items found.

All unitary patents fall within the competence of the Unified Patent Court (UPC). Additionally, classical validations of European Patents in states which have ratified the UPC agreement are within the competence of the UPC (unless opted_out).

Can I obtain a Unitary Patent now?

Yes – this can be done as part of the grant procedures at the EPO. It is similar to the existing validation procedures, except it is performed at the EPO and the timescale is quite fast: the request for a Unitary Patent must be filed no later than one month after the date of publication of the mention of the grant in the European Patent Bulletin, and a translation must be supplied.

Your usual EIP contact can advise on this if of interest.

What about other validated EP patents?

During the transitional period, national courts and the UPC share competence in respect of classical validations of European patents (that are not opted out) in the member states participating in the UPC.

If use of the UPC is important, there is merit in being the party to initiate litigation so that you choose the forum. If an action is brought in a national court, it may no longer be possible to use the UPC for an action involving the same parties in respect of that patent. This is expected to be a complex area of law due to different relevant regulations, and EIP Latest are able to advise on the appropriate strategy for your situation.

What if an EP patent has been opted_out?

It is possible to withdraw the opt_out, provided that no national litigation has taken place. This would then allow the use of the UPC in respect of that patent. An opt_out can only be done once, so if a patent is opted out and and then that opt_out is withdrawn, the patent cannot be opted out again.

The Latest Thought Leadership pieces in the Content Hub

See all articles

What languages does the UPC use?

November 1, 2022

Central Division Proceedings at the central division are in the language in which the patent was granted (i.e., either French, German or English).

Geographic Scope of the UPC and Unitary Patent

February 22, 2023

The grant of a European Patent allows patent rights to be obtained in respect of over 35 states by means of the respective validation procedures for those states.

Opt-out decision

December 2, 2022

Owners of European patent rights (both pending and granted patents) need to decide, in respect of each right individually, whether to opt out of the Unified Patent Court ("UPC") system.

Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Latest Insights

Showing 0 of 100

The UPC After Three Years: From Experiment to Enforcement Forum

15 July 2026

1,282 cases filed at the UPC in three years: infringement actions have surged while revocation filings stayed flat, easing fears the Court would become a European patent graveyard.

Choosing your SEP battleground: UPC, Germany or UK?

07 June 2026

Choosing the right venue for SEP litigation can significantly influence the outcome of FRAND disputes. This article compares the UPC, German and UK courts, examining their approaches to injunctions, FRAND defences, rate-setting and enforcement. It highlights the strategic advantages of each jurisdiction and explains why many SEP owners are increasingly turning to the UK and UPC as part of their European enforcement strategy.

Synthetic Lethality & AI: IP Strategy in Oncology

26 May 2026

This article explores the resurgence of synthetic lethality in precision oncology, highlighting how AI and machine learning are accelerating the discovery of new therapeutic targets. It also examines growing clinical activity, investment, and the evolving intellectual property challenges shaping this emerging field.

Inside the Visser AI Launch Party

20 May 2026

EIP has officially launched Visser AI®, our hybrid intelligence service for patent drafting and prosecution. Watch the launch film from our event at The Boundary in Shoreditch, and discover how our team of European and US patent attorneys — working with the Patently AI platform , delivers faster, lower-cost work at the EPO, USPTO and beyond.

Protecting Your Startup: Five Intellectual Property Mistakes to Avoid

20 May 2026

Early‑stage startups often focus on product development and fundraising, but overlooking intellectual property (IP) can seriously damage long‑term value. This article explores five common IP mistakes startups make, with a particular focus on patents. It covers the risks of filing patents without professional advice, making public disclosures too early, failing to put enforceable contracts in place with third parties, misunderstanding what patent rights actually provide, and neglecting to develop a clear IP strategy. By highlighting these pitfalls and offering practical guidance, the article helps startups protect their innovations, strengthen their commercial position, and improve their prospects with investors.

Technology, Patents, and Sport

13 May 2026

VAR, goal-line tech, AI 3D player avatars, wearable trackers, the technology reshaping the 2026 World Cup and elite sport rests on a patent system that makes the R&D investment behind it worth taking.

Patents or Trade Secrets? When to Patent in Deep Tech Innovation

11 May 2026

Deep tech companies face unique IP challenges due to long development cycles, high upfront investment, and complex technologies that combine products and processes. This article explores when patents, trade secrets, or a combination of both offer the strongest protection. It explains how factors such as detectability, reverse engineering risk, disclosure to third parties, and employee mobility should shape IP strategy decisions. While patents are often best suited to externally visible or licensable technologies, trade secrets can be highly effective for internal processes and know‑how that deliver performance or cost advantages.

Is Your AI Conversation Privileged?

08 May 2026

Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.

The evolution of nucleic acid sequencing and what it means for Genomics and IP

27 April 2026

This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.

World IP Day: The big ideas shaping IP's fastest-moving fields

24 April 2026

For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.

Meet the EIP team heading to INTA 2026 in London

23 April 2026

INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.

National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?

27 March 2026

National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.

Make your bio(pharma) IP investment ready

22 March 2026

This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.

Are professional guidelines making Patent Attorneys too cautious on AI?

19 February 2026

As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.

Beyond CRISPR: Precision to Platform

23 January 2026

Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.